Clinical Trial Update: A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Hepalatide in combination with TAF and PEG-IFN as a finite treatment for chronic hepatitis B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Hepalatide
• PEG-IFN (pegylated interferon) (pegylated interferon)
• TAF (tenofovir alafenamide) (tenofovir alafenamide)

Snippet

Sponsor: Shanghai HEP Pharmaceutical Co., Ltd. | Conditions: Chronic Hepatitis B | Phase 2 | Status: COMPLETED